<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-id journal-id-type="hwp">spcep</journal-id>
<journal-title>Cephalalgia</journal-title>
<issn pub-type="ppub">0333-1024</issn>
<issn pub-type="epub">1468-2982</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0333102412470216</article-id>
<article-id pub-id-type="publisher-id">10.1177_0333102412470216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Issue Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pearls and pitfalls in experimental models of spreading depression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ayata</surname><given-names>Cenk</given-names></name>
<xref ref-type="corresp" rid="corresp1-0333102412470216"/>
</contrib>
</contrib-group>
<aff id="aff1-0333102412470216">Neurovascular Research Lab, Department of Radiology, and Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, USA</aff>
<author-notes>
<corresp id="corresp1-0333102412470216">Cenk Ayata, Massachusetts General Hospital, Harvard Medical School, 149 13th St., Room 6408, Charlestown, MA 02129, USA. Email: <email>cayata@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>8</issue>
<issue-title>Special Issue on Pearls and Pitfalls in Headache Research</issue-title>
<fpage>604</fpage>
<lpage>613</lpage>
<history>
<date date-type="received"><day>13</day><month>8</month><year>2012</year></date>
<date date-type="rev-recd"><day>10</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>11</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© International Headache Society 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">International Headache Society</copyright-holder>
</permissions>
<abstract>
<sec id="sec17-0333102412470216"><title>Background</title>
<p>Spreading depression (SD) is the electrophysiological substrate of migraine aura and a potential trigger for headache. Since its discovery by Leão in 1944, SD has transformed from being viewed as an epiphenomenon into a therapeutic target relevant in the pathophysiology of migraine and brain injury.</p>
</sec>
<sec id="sec18-0333102412470216"><title>Aim</title>
<p>Despite decades of research, the underpinnings of SD are still poorly understood, hampering our efforts to selectively block its initiation and spread. Experimental models have nevertheless been useful to measure the likelihood of SD occurrence (i.e. SD susceptibility) and characterize genetic, physiological and pharmacological modulation of SD in search of potential therapies, such as in migraine prophylaxis and stroke. Here, I review experimental SD susceptibility endpoints and surrogates, and minimum essential model requirements to improve their utility in drug screening.</p>
</sec>
<sec id="sec19-0333102412470216"><title>Conclusion</title>
<p>A critical reappraisal of strengths and caveats of experimental models of SD susceptibility is needed to set standards and improve data quality, interpretation and reconciliation.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Spreading depression</kwd>
<kwd>migraine</kwd>
<kwd>aura</kwd>
<kwd>animal models</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0333102412470216" sec-type="intro"><title>Introduction</title>
<p>Spreading depression (SD) is an intense neuronal and glial depolarization wave that slowly propagates in brain tissue (∼3 mm/min) by way of gray matter contiguity. The near-complete loss of membrane potential is a result of massive transmembrane ionic and water shifts, including a K<sup>+</sup> and glutamate efflux, and Na<sup>+</sup>, Ca<sup>2+</sup> and water influx, which last up to a minute and does not lead to injury in otherwise normal brain tissue. It is believed that the rise in extracellular K<sup>+</sup> and glutamate act as chemical signals diffusing to and depolarizing adjacent cells, and in this way the depolarization slowly spreads regardless of functional or vascular divisions. For the released K<sup>+</sup> and glutamate to reach the critical depolarization threshold of adjacent cells, high neuronal and synaptic density and low extracellular space volume are required; therefore, white matter is characteristically resistant to SD. All these ionic and water shifts create a signature extracellular negative slow potential shift (aka DC shift) accompanied by suppression of action potentials and synaptic activity (<xref ref-type="fig" rid="fig1-0333102412470216">Figure 1</xref>). As a result, electrocorticogram (ECoG) is depressed, hence the historical term “spreading depression” originally coined by Leão (<xref ref-type="bibr" rid="bibr1-0333102412470216">1<bold>**</bold></xref>).
<fig id="fig1-0333102412470216" position="float"><label>Figure 1.</label><caption><p>Cortical spreading depression (SD) triggered by a suprathreshold stimulus delivered on to the frontal cortex is detected by a glass micropipette a few mm away in the parietal cortex after a latency accounting for its slow propagation speed. Note the large negative slow (DC) potential shift that lasts approximately 30 sec (upper tracing) and the concurrent electrocorticogram (ECoG) suppression (lower tracing) that outlasts the DC shift by several minutes. The DC shift accompanied by ECoG suppression is the most reliable electrophysiological signature of SD. Tracings are from a rat under isoflurane and nitrous oxide anesthesia. Vertical scale 20 mV DC, 0.4 mV ECoG; horizontal scale 1 min.</p></caption><graphic xlink:href="10.1177_0333102412470216-fig1.tif"/>
</fig></p>
<p>Since the discovery of SD decades ago, similarities between the electrophysiological properties of SD and the neurological signs and symptoms during migraine aura suggested a causative link between the two (<xref ref-type="bibr" rid="bibr2-0333102412470216">2</xref><xref ref-type="bibr" rid="bibr3-0333102412470216"/>–<xref ref-type="bibr" rid="bibr4-0333102412470216">4</xref>). A large body of evidence now supports the SD theory of migraine (<xref ref-type="bibr" rid="bibr5-0333102412470216">5</xref>). Moreover, experimental evidence also suggests that SD can trigger headache (<xref ref-type="bibr" rid="bibr6-0333102412470216">6</xref><xref ref-type="bibr" rid="bibr7-0333102412470216"/><xref ref-type="bibr" rid="bibr8-0333102412470216"/><xref ref-type="bibr" rid="bibr9-0333102412470216"/>–<xref ref-type="bibr" rid="bibr10-0333102412470216">10<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr11-0333102412470216">11</xref>). Although whether an asymptomatic SD triggers migraine headache without a perceived aura is still debated, suppression of SD susceptibility by migraine prophylactic drugs as a class effect (<xref ref-type="bibr" rid="bibr12-0333102412470216">12</xref><xref ref-type="bibr" rid="bibr13-0333102412470216"/>–<xref ref-type="bibr" rid="bibr14-0333102412470216">14<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr15-0333102412470216">15</xref><xref ref-type="bibr" rid="bibr16-0333102412470216"/><xref ref-type="bibr" rid="bibr17-0333102412470216"/>–<xref ref-type="bibr" rid="bibr18-0333102412470216">18</xref>) supported this notion since these drugs have been equally efficacious in migraine with or without a perceived aura. Therefore, SD is now considered a potential therapeutic target in migraine, and experimental models of SD susceptibility are increasingly being used to screen for migraine drug candidates. A range of experimental models of SD has been developed, although the sensitivity and specificity and the predictive value of each model have not been systematically investigated, and a consensus is still lacking.</p>
</sec>
<sec id="sec2-0333102412470216"><title>In vitro vs. in vivo models</title>
<p>In vitro models, such as isolated retina and brain slices, have been used in the past to study the effects of various pharmacological agents on SD properties. These models bypass the blood-brain barrier and eliminate hemodynamic, pharmacokinetic, anesthesia-related and systemic physiological factors. However, tissue oxygenation and metabolism differ from the in vivo state because of the absence of blood flow (<xref ref-type="bibr" rid="bibr19-0333102412470216">19</xref>,<xref ref-type="bibr" rid="bibr20-0333102412470216">20</xref>), exposure to hypoxia and trauma during experimental preparation may confound the results, and it is difficult to judge the clinically relevant drug concentrations when directly superfused in vitro. Therefore, convenience of the relatively high-throughput in vitro drug screening is offset by difficulties in extrapolating the in vitro results to in vivo efficacy.</p>
<p>In vivo models have been for the most part limited to cerebral cortex because of ease of access. Although most studies have been in rodents, a wide variety of species from pigeons to cats and monkeys have been used (<xref ref-type="bibr" rid="bibr21-0333102412470216">21</xref>,<xref ref-type="bibr" rid="bibr22-0333102412470216">22</xref>). There is a fair degree of interspecies variability in SD susceptibility. In general, the larger the brain is, the lower the susceptibility (e.g. mouse vs. rat). In addition, gyrencephalic species (e.g. cats) are less susceptible than lissencephalic species (e.g. rodents). Species differences in SD susceptibility, and their determinants, have not been systematically studied. Although increasing astrocyte/neuron ratios in higher species have frequently been cited as the cause (<xref ref-type="bibr" rid="bibr23-0333102412470216">23</xref>,<xref ref-type="bibr" rid="bibr24-0333102412470216">24</xref>), it is unlikely to be the only determinant.</p>
</sec>
<sec id="sec3-0333102412470216"><title>Methods to trigger SD</title>
<p>SD is triggered when a sufficiently intense depolarizing stimulus raises extracellular [K<sup>+</sup>] above a threshold in a minimum critical volume of tissue, estimated to be approximately 12 mM and 1 mm<sup>3</sup>, respectively, in rodent brain (<xref ref-type="bibr" rid="bibr25-0333102412470216">25</xref><xref ref-type="bibr" rid="bibr26-0333102412470216"/>–<xref ref-type="bibr" rid="bibr27-0333102412470216">27</xref>). The depolarizing stimulus is most commonly electrical, chemical or mechanical.</p>
<p>Electrical stimulation is one of the most direct methods to assess SD susceptibility (<xref ref-type="bibr" rid="bibr14-0333102412470216">14<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr28-0333102412470216">28</xref>,<xref ref-type="bibr" rid="bibr29-0333102412470216">29</xref>). A single square pulse of stepwise escalating cathodal charge is applied at regular intervals (e.g. every 4–5 minutes) until an SD is triggered (<xref ref-type="fig" rid="fig2-0333102412470216">Figure 2</xref>). The product of stimulus current (ampere) and duration (seconds) that triggers an SD is then taken as the charge intensity threshold (coulomb). High-frequency train stimulation of increasing intensity or duration is an alternative approach. The absolute threshold values in any experimental setting critically depend on methodological details. Electrode properties and electrode-tissue contact determine the stimulus geometry, which heavily influences the charge intensity required to trigger an SD. Stimulus geometry is best controlled by a cortical cup electrode (<xref ref-type="bibr" rid="bibr26-0333102412470216">26</xref>); however, this is not always available or practical. Instead, both unipolar and concentric or parallel bipolar electrodes can be used. We favor the latter since stimulus polarity can be alternated to minimize oxidation. In all cases, slight differences in tip separation or insulation between two electrodes, or changes in the same electrode due to wear and tear over time, can result in different absolute threshold values. Therefore, it is important not to rely on historical controls when studying modulation of electrical threshold. Electrical threshold yields categorical (i.e. non-parametric) data, and often shows higher variability compared to chemical depolarizing agents because of irregularities at the electrode-tissue contact (e.g. bleeding or drying).
<fig id="fig2-0333102412470216" position="float"><label>Figure 2.</label><caption><p>Direct electrical stimulation of cortex with stepwise escalating charge intensities (single square pulses of alternating polarity using a bipolar electrode in this example) triggers a spreading depression (SD) when the threshold is reached. The stimulus intensity steps depend on the electrode and the species, and can be adjusted according to the hypothesis being tested; if testing a drug or mutation that significantly lowers the threshold, it would be important to start at a low stimulus intensity with small step increases. Tracing is from a representative rat under isoflurane and nitrous oxide anesthesia. Vertical scale bar 10 mV; horizontal scale bar 2 min.</p></caption><graphic xlink:href="10.1177_0333102412470216-fig2.tif"/>
</fig></p>
<p>The most common chemical depolarizing agent used to determine SD susceptibility is concentrated KCl solution (often 50 mM or higher), although glutamate receptor agonists (e.g. N-methyl-<sc>D</sc>-aspartate (NMDA)), Ca<sup>2+</sup> channel openers or ionophores (e.g. Bay K8644), and Na<sup>+</sup> channel activators (e.g. aconitine) can all trigger SD. Depolarizing agents can be applied topically (<xref ref-type="bibr" rid="bibr14-0333102412470216">14<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr30-0333102412470216">30</xref>), or intraparenchymally using a pneumatic injection or microdialysis system (<xref ref-type="bibr" rid="bibr31-0333102412470216">31</xref>,<xref ref-type="bibr" rid="bibr32-0333102412470216">32</xref>). To determine the SD threshold, one can then escalate the concentration of the depolarizing agent (<xref ref-type="fig" rid="fig3-0333102412470216">Figure 3</xref>), or the volume injected, in a stepwise manner (<xref ref-type="bibr" rid="bibr33-0333102412470216">33</xref>,<xref ref-type="bibr" rid="bibr34-0333102412470216">34</xref>).
<fig id="fig3-0333102412470216" position="float"><label>Figure 3.</label><caption><p>Topical application of stepwise increasing concentrations of KCl solution triggers a spreading depression (SD) at a threshold concentration of 40 mM. As with electrical stimulation, the KCl concentration steps can be tailored to the hypothesis; for example, when studying a drug or mutation that is anticipated to significantly lower the threshold, testing should start at a lower concentration with smaller step increases. Tracing is from a representative mouse under isoflurane and nitrous oxide anesthesia. Vertical scale bar 10 mV; horizontal scale bar 1 min.</p></caption><graphic xlink:href="10.1177_0333102412470216-fig3.tif"/>
</fig></p>
<p>Alternatively, a constant suprathreshold concentration (e.g. 1 M KCl) can be applied continuously to trigger repetitive SDs (<xref ref-type="fig" rid="fig4-0333102412470216">Figure 4</xref>) and determine their frequency (<xref ref-type="bibr" rid="bibr14-0333102412470216">14<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr30-0333102412470216">30</xref>,<xref ref-type="bibr" rid="bibr35-0333102412470216">35</xref>). An important potential caveat of SD frequency endpoint is the absolute and relative refractory periods during which a subsequent SD cannot be triggered (<xref ref-type="bibr" rid="bibr36-0333102412470216">36</xref>). Importantly, longer SD durations are associated with prolonged refractory periods and lower SD frequencies, which may be misinterpreted as lower susceptibility. In such cases, the total cumulative SD duration (e.g. per hour) may be an alternative endpoint. Because SD frequency yields continuous data and is less prone to cortical surface irregularities, it tends to be statistically more powerful compared to electrical threshold. Both KCl concentration threshold and KCl-induced SD frequency critically depend on the cranial window diameter and the presence of dura. Therefore, these parameters must be identical across animals and experimental groups, different experimenters, and if possible, different labs.
<fig id="fig4-0333102412470216" position="float"><label>Figure 4.</label><caption><p>Continuous topical KCl application on occipital cortex (horizontal line on top) triggers repetitive spreading depression (SD) waves recorded from the parietal cortex. Occasional small-amplitude SDs are included in the count if they are larger than 5 mV (arrowhead). Note the suppression and recovery of the electrocorticogram (ECoG) after each SD (arrows), which often helps differentiate electrical noise from true SDs when the latter is very small (dot). Tracing is from a representative rat under isoflurane and nitrous oxide anesthesia. Vertical scale bar 10 mV; horizontal scale bar 5 min.</p></caption><graphic xlink:href="10.1177_0333102412470216-fig4.tif"/>
</fig></p>
<p>Mechanical stimulation has also been used to assess SD susceptibility. However, it is difficult to titrate to determine a threshold. Therefore, SD susceptibility is measured by how often a single mechanical stimulus triggers SD, i.e. an all or none response (<xref ref-type="bibr" rid="bibr37-0333102412470216">37</xref>). Repetitive assessment can be problematic because of poor reproducibility of the stimulus and cumulative traumatic injury. Furthermore, mechanically induced SD appears to have a different pharmacological profile compared to chemical or electrical SD induction (<xref ref-type="bibr" rid="bibr38-0333102412470216">38</xref>,<xref ref-type="bibr" rid="bibr39-0333102412470216">39</xref>). Other methods to trigger SD include high-frequency afferent pathway stimulation and focal cerebral ischemia (<xref ref-type="bibr" rid="bibr40-0333102412470216">40</xref>), but these are not practical for high-throughput drug screening.</p>
</sec>
<sec id="sec4-0333102412470216"><title>Methods to detect SD</title>
<p>Electrophysiologically, the characteristic extracellular negative slow potential shift is the gold standard to detect SD. This is often briefly preceded by a burst of neuronal firing that can be detected by single unit recordings, followed by a longer lasting suppression of neuronal firing and ECoG activity. Although this pattern of single unit activity can be used as a surrogate for the slow potential shift (<xref ref-type="bibr" rid="bibr37-0333102412470216">37</xref><xref ref-type="bibr" rid="bibr38-0333102412470216"/>–<xref ref-type="bibr" rid="bibr39-0333102412470216">39</xref>), it is neither more sensitive nor more specific than the latter, does not directly inform about the depolarization duration or amplitude, and cannot be used if the test drug has a direct inhibitory effect on neuronal firing (e.g. tetrodotoxin).</p>
<p>An alternative method to detect SD in vivo is diffusion-weighted magnetic resonance imaging (MRI) (<xref ref-type="bibr" rid="bibr41-0333102412470216">41</xref>). The advantages of being non-invasive and three dimensional are offset by relatively low spatial and temporal resolution. Therefore, MRI may be superior to traditional electrophysiological methods only in larger gyrencephalic species and low SD repetition rates. SD is also associated with characteristic optical intrinsic signal transients (<xref ref-type="bibr" rid="bibr42-0333102412470216">42</xref>). These are caused by changes in light absorption and scattering properties of the tissue due to transmembrane ionic and water shifts, as well as changes in tissue hemoglobin concentration. Alternatively, one can also monitor the large amplitude blood flow transients to detect SD (<xref ref-type="bibr" rid="bibr38-0333102412470216">38</xref>,<xref ref-type="bibr" rid="bibr43-0333102412470216">43</xref>). These are complementary surrogates, but should not replace the slow potential shift as the standard method to detect SD.</p>
</sec>
<sec id="sec5-0333102412470216"><title>Relevant SD attributes</title>
<p>SD susceptibility is defined as the likelihood of the brain tissue to develop and sustain SD. There are various experimental models and approaches that have been used by different labs to assess SD susceptibility. Physiological processes interrogated by each model, and the translational value of their readouts, have not been established. Of course, each model has strengths and pitfalls, and agreement of results among models remains to be established.</p>
<p>Arguably the most relevant measure of SD susceptibility is the threshold intensity of electrical charge or threshold concentration or volume of the depolarizing agent (e.g. KCl) that triggers an SD, as described above. The threshold topical electrical stimulation intensity and the threshold KCl concentration for SD induction show excellent concordance (<xref ref-type="bibr" rid="bibr34-0333102412470216">34</xref>). Interestingly, continuous topical KCl-induced SD frequency has also showed complete concordance with electrical SD threshold when studied in the same animal in our hands (<xref ref-type="bibr" rid="bibr14-0333102412470216">14<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr16-0333102412470216">16</xref>,<xref ref-type="bibr" rid="bibr17-0333102412470216">17</xref>,<xref ref-type="bibr" rid="bibr28-0333102412470216">28</xref>). The relationship is inverse, such that lower SD thresholds yield higher SD frequencies and vice versa. Importantly, SD frequency has a theoretical ceiling determined by the SD duration and the absolute refractory period during which a subsequent SD cannot be initiated, which is estimated to be two to three minutes. Therefore, one cannot trigger more than 20–30 SDs in one hour regardless of the intensity of stimulation, a ceiling that we have observed in highly susceptible mutant mouse strains (<xref ref-type="bibr" rid="bibr30-0333102412470216">30</xref>).</p>
<p>Other measures of the slow potential shift, such as its propagation speed, duration, and amplitude, may also be relevant, although how these measures relate to SD susceptibility and their predictive value have not been studied. In our own pooled data from 87 controlled cohorts with genetic, physiological or pharmacological manipulation (<italic>n</italic> = 766 mice and rats) published between 2000 and 2012 (<xref ref-type="bibr" rid="bibr14-0333102412470216">14<bold>**</bold></xref>,<xref ref-type="bibr" rid="bibr16-0333102412470216">16</xref>,<xref ref-type="bibr" rid="bibr17-0333102412470216">17</xref>,<xref ref-type="bibr" rid="bibr28-0333102412470216">28</xref>,<xref ref-type="bibr" rid="bibr30-0333102412470216">30</xref>,<xref ref-type="bibr" rid="bibr34-0333102412470216">34</xref>,<xref ref-type="bibr" rid="bibr35-0333102412470216">35</xref>,<xref ref-type="bibr" rid="bibr44-0333102412470216">44</xref>,<xref ref-type="bibr" rid="bibr45-0333102412470216">45</xref>), there was strong correspondence between susceptibility and propagation speed (<xref ref-type="table" rid="table1-0333102412470216">Table 1</xref>). Propagation speed had modest sensitivity (67%) and specificity (76%) in predicting a change in SD susceptibility, with positive and negative predictive values of 84% and 56%, respectively (κ = 0.75; 95% confidence interval (CI) = 0.62–0.89). In contrast, SD duration and amplitude did not show a consistent relationship to SD susceptibility.
<table-wrap id="table1-0333102412470216" position="float"><label>Table 1.</label><caption><p>The relationship between SD susceptibility and other SD attributes.</p></caption>
<graphic alternate-form-of="table1-0333102412470216" xlink:href="10.1177_0333102412470216-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>(% of all cohorts)</th>
<th colspan="3">SD speed</th>
<th colspan="3">SD duration</th>
<th colspan="3">SD amplitude</th>
</tr>
<tr><th>SD susceptibility</th>
<th><italic>Increased</italic></th>
<th><italic>Unchanged</italic></th>
<th><italic>Decreased</italic></th>
<th><italic>Increased</italic></th>
<th><italic>Unchanged</italic></th>
<th><italic>Decreased</italic></th>
<th><italic>Increased</italic></th>
<th><italic>Unchanged</italic></th>
<th><italic>Decreased</italic></th>
</tr></thead>
<tbody align="left">
<tr>
<td><italic>Increased</italic></td>
<td>27</td>
<td>8</td>
<td>4</td>
<td>31</td>
<td>35</td>
</tr>
<tr>
<td><italic>Unchanged</italic></td>
<td>4</td>
<td>27</td>
<td>4</td>
<td>4</td>
<td>31</td>
<td>35</td>
</tr>
<tr>
<td><italic>Decreased</italic></td>
<td>13</td>
<td>17</td>
<td>3</td>
<td>21</td>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>κ</td>
<td colspan="3">0.75 (0.84)</td>
<td colspan="3">0.17</td>
<td colspan="3">0.00</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0333102412470216"><p>SD: spreading depression.</p></fn>
<fn id="table-fn2-0333102412470216"><p>Numbers indicate percentage distribution of susceptibility outcome (threshold and/or frequency) vs. speed, duration and amplitude outcomes when measured in the same cohort, categorized based on statistically significant increase or decrease, or no change. Sensitivity, specificity, and positive and negative predictive values of SD speed to predict SD susceptibility were calculated from true positives (attribute changes in the same direction as susceptibility), true negatives (neither susceptibility nor attribute shows a change), false negatives (attribute fails to show a change when susceptibility is changed), and false positives (attribute shows a change when susceptibility is unchanged, or attribute shows a change in the direction opposite to the change in susceptibility). Kappa (κ)statistic was calculated with quadratic weighting. The corrected κ value as proportion of maximum possible (given the observed marginal frequencies) is also provided in parentheses. κ = 1 is the theoretical maximum, while κ &gt; 0.75 is regarded as excellent agreement.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Although based on these data, propagation speed may be an acceptable surrogate to detect a change in SD susceptibility, its clinical relevance is not clear. Moreover, there are potential caveats associated with these surrogates. For example, the propagation speed as well as the duration decrease with each successive SD to reach a plateau as much as 25% lower than the initial values after a few SDs. Therefore, care should be taken to not trigger SDs inadvertently during cranial surgery as these will make subsequent SD speeds and durations appear lower than normal. We recommend monitoring accidental SD occurrence, for example, by non-invasive laser Doppler flowmetry, during experimental preparation, particularly in rodents where SD susceptibility is inherently high.</p>
<p>When monitoring SD occurrence for threshold determination, one should keep in mind that SDs can fail to propagate, especially when SD susceptibility is dramatically reduced (<xref ref-type="bibr" rid="bibr34-0333102412470216">34</xref>). Because of this, the rate of SD detection can vary inversely with the distance between the recording and stimulation sites. To minimize this confounder, we adopted the use of two recording sites, one sufficiently close to the stimulation site (but not too close to be directly depolarized during stimulation, typically a couple of mm), and one farther away. This arrangement allows the detection of most if not all SDs, as well as the calculation of propagation failure rate between the two recording sites.</p>
</sec>
<sec id="sec6-0333102412470216"><title>Recommended quality measures</title>
<sec id="sec7-0333102412470216"><title>In vivo vs. in vitro testing</title>
<p>In general, in vitro models (e.g. isolated retina) may provide a high-throughput system for initial SD susceptibility testing (<xref ref-type="bibr" rid="bibr46-0333102412470216">46</xref>,<xref ref-type="bibr" rid="bibr47-0333102412470216">47</xref>). However, especially in drug screening, promising hits must then be fully characterized in vivo upon systemic administration, preferably in more than one species and both sexes. Although testing in a gyrencephalic species may be intuitive, there is yet no evidence to suggest that efficacy in gyrencephalic species better predicts efficacy in human compared to rodent models. Migraine is a genetic disease, and the recent development of transgenic mouse models expressing human migraine mutations (<xref ref-type="bibr" rid="bibr28-0333102412470216">28</xref>,<xref ref-type="bibr" rid="bibr30-0333102412470216">30</xref>,<xref ref-type="bibr" rid="bibr45-0333102412470216">45</xref>,<xref ref-type="bibr" rid="bibr48-0333102412470216">48</xref><xref ref-type="bibr" rid="bibr49-0333102412470216"/>–<xref ref-type="bibr" rid="bibr50-0333102412470216">50</xref>) provides an excellent opportunity to test drug efficacy in a genetically susceptible population.</p>
</sec>
<sec id="sec8-0333102412470216"><title>Anesthesia</title>
<p>Anesthesia modulates SD susceptibility (<xref ref-type="bibr" rid="bibr35-0333102412470216">35</xref>,<xref ref-type="bibr" rid="bibr51-0333102412470216">51</xref><xref ref-type="bibr" rid="bibr52-0333102412470216"/><xref ref-type="bibr" rid="bibr53-0333102412470216"/><xref ref-type="bibr" rid="bibr54-0333102412470216"/><xref ref-type="bibr" rid="bibr55-0333102412470216"/><xref ref-type="bibr" rid="bibr56-0333102412470216"/>–<xref ref-type="bibr" rid="bibr57-0333102412470216">57</xref>). Inhalational anesthetics such as isoflurane and nitrous oxide, and particularly the NMDA receptor blocker and dissociative anesthetic ketamine, suppress SD induction and hinder propagation. Propofol was recently reported to suppress SD as well (<xref ref-type="bibr" rid="bibr58-0333102412470216">58</xref>), although this remains to be confirmed. In our experience, barbiturates, urethane and α-chloralose do not significantly inhibit SD, and should be the first choice when feasible. However, an additional consideration is the ease with which anesthesia can be induced and maintained over time while preserving systemic physiology (e.g. arterial blood gas and pressure). Deep anesthesia often results in hypotension, which is a potential confounder when determining SD frequency (see below). Significant respiratory depression necessitates mechanical ventilation, a particularly challenging task in mice. These side effects are common with barbiturates, urethane and α-chloralose. In general, an anesthetic that acts on the same target as the drug to be tested should be avoided (e.g. barbiturate anesthesia when testing a drug that acts on γ-amino butyric acid (GABA)<sub>A</sub> receptors, or ketamine when testing the efficacy of an NMDA receptor blocker). Anesthesia must be carefully tailored for each study in order not to confound the results and diminish the sensitivity of the employed assays. The convenience of anesthesia induction and maintenance by a given anesthetic should be weighed against its direct impact on SD susceptibility, and possible interactions between the anesthetic and the modulator (e.g. mutation or drug) to be tested.</p>
</sec>
<sec id="sec9-0333102412470216"><title>Systemic physiology</title>
<p>It is imperative that systemic physiology be monitored, and when necessary, controlled (e.g. mechanical ventilation) in experimental models of SD susceptibility. Arterial blood pressure is inversely related to SD duration (<xref ref-type="bibr" rid="bibr59-0333102412470216">59</xref>,<xref ref-type="bibr" rid="bibr60-0333102412470216">60</xref>). Hypotension, even if mild, prolongs SD duration, which in turn prolongs the absolute refractory period. As a result, SD frequency during continuous topical KCl stimulation will be reduced. Hence, a drug that consistently reduces blood pressures may yield lower SD frequencies, and vice versa (<xref ref-type="bibr" rid="bibr6-0333102412470216">6</xref>,<xref ref-type="bibr" rid="bibr61-0333102412470216">61</xref>). Whether blood pressure also directly alters SD threshold has not been tested. Arterial blood gas and pH are also expected to influence SD susceptibility, but the relationship is less straightforward and has not been well investigated. Nevertheless, maintaining these values within normal physiological ranges is good practice. We perform endotracheal intubation and mechanical ventilation routinely in rats and when necessary in mice (e.g. barbiturate anesthesia), as the latter species is more fragile and tends to get hypotensive with prolonged anesthesia and mechanical ventilation. Of note, certain mouse strains are more resilient and can maintain their blood pressure for longer periods of anesthesia and ventilation. Blood glucose is also an important factor. Hyperglycemia inhibits SD susceptibility (<xref ref-type="bibr" rid="bibr62-0333102412470216">62</xref><xref ref-type="bibr" rid="bibr63-0333102412470216"/><xref ref-type="bibr" rid="bibr64-0333102412470216"/>–<xref ref-type="bibr" rid="bibr65-0333102412470216">65</xref>), whereas hypoglycemia prolongs SD durations (<xref ref-type="bibr" rid="bibr64-0333102412470216">64</xref>). Therefore, blood glucose measurements further improve the consistency, particularly when genetic, physiological or pharmacological interventions are anticipated to alter this parameter. Overnight fasting generally stabilizes the systemic physiology and ameliorates hyperglycemia during surgery and subsequent interventions, but also tends to enhance SD susceptibility directly. Lastly, body temperature must also be regulated under anesthesia.</p>
</sec>
<sec id="sec10-0333102412470216"><title>Surgical preparation and maintenance</title>
<p>Surgical preparation and maintenance of the craniotomy are also critical for reliable and consistent results and intra- and interobserver reproducibility. Of course, cortical injury due to trauma or heat during craniotomy, and bleeding or drying can all affect SD susceptibility. The cortex must be kept moist by artificial cerebrospinal fluid (CSF) or physiologic saline to maintain isotonicity during the experiments. Dura must be removed prior to electrical and chemical stimulation in rats and larger animals, but can be left intact in mice, as it is sufficiently thin and difficult to remove in an atraumatic fashion.</p>
</sec>
<sec id="sec11-0333102412470216"><title>SD susceptibility</title>
<p>The most direct and relevant SD attribute is susceptibility, monitored using intraparenchymal extracellular microelectrode recordings of slow potential shift combined with ECoG activity. We prefer to determine the electrical threshold on one hemisphere, and KCl-induced SD frequency on the other hemisphere of the same animal; these two methods are non-overlapping but complementary measures of SD susceptibility and correlate well. We also routinely measure SD speed, duration and amplitude, and use them to obtain additional physiological insight.</p>
</sec>
<sec id="sec12-0333102412470216"><title>Pharmacokinetic factors</title>
<p>Careful consideration of pharmacokinetic factors (e.g. absorption and elimination rates and routes, plasma and brain levels), seeking a dose-response relationship, testing the efficacy of repeated or chronic dosing paradigms in addition to a single dose, and including a positive control (e.g. a drug known to produce the sought effect) among the cohorts, all minimize the type II error.</p>
</sec>
<sec id="sec13-0333102412470216"><title>Conduct of research</title>
<p>Last but not least, responsible conduct of research must be ensured by single or double blinding, and independent confirmation of data in a second laboratory. Inclusion of a negative control (e.g. a drug known to be ineffective) helps minimize type I error. In this context, Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for reporting animal research are worth adopting universally (<xref ref-type="bibr" rid="bibr66-0333102412470216">66</xref>).</p>
</sec>
</sec>
<sec id="sec14-0333102412470216"><title>Future directions and unmet needs</title>
<p>As SD is increasingly recognized as a potential therapeutic target not only in migraine but also in stroke and other brain injury states, research into the determinants and modulators of SD susceptibility (<xref ref-type="fig" rid="fig5-0333102412470216">Figure 5</xref>) has been gaining momentum (<xref ref-type="bibr" rid="bibr67-0333102412470216">67</xref>). As more experimental data on SD susceptibility become available, its predictive and translational therapeutic value will be better defined. In order to ensure efficient progress in the field, there is a need for an in-depth and timely discussion of relevant models and attributes toward a consensus standardization of the experimental approaches used in different labs.
<fig id="fig5-0333102412470216" position="float"><label>Figure 5.</label><caption><p>There are numerous modulators of spreading depression (SD) susceptibility, intrinsic or environmental, some of which are modifiable. Checkmarks indicate existing supportive evidence experimentally or clinically. A detailed discussion of pharmacological targets can be found in Ayata (<xref ref-type="bibr" rid="bibr13-0333102412470216">13</xref>).</p></caption><graphic xlink:href="10.1177_0333102412470216-fig5.tif"/>
</fig></p>
</sec>
</body>
<back>
<sec id="sec15-0333102412470216"><title>Funding</title>
<p>This work was funded in part by the United States National Institutes of Health (NIH) (NS061505) and the Andrew David Heitman Neuroendovascular Research Fund from the Andrew David Heitman Foundation.</p>
</sec>
<sec id="sec16-0333102412470216"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0333102412470216"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leão</surname><given-names>AAP</given-names></name></person-group>. <article-title>Spreading depression of activity in cerebral cortex</article-title>. <source>J Neurophysiol</source> <year>1944</year>; <volume>7</volume>: <fpage>359</fpage>–<lpage>390</lpage>. <comment><bold>**First report defining spreading depression and its basic features</bold></comment>.</citation></ref>
<ref id="bibr2-0333102412470216"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leão</surname><given-names>AAP</given-names></name><name><surname>Morison</surname><given-names>RS</given-names></name></person-group>. <article-title>Propagation of spreading cortical depression</article-title>. <source>J Neurophysiol</source> <year>1945</year>; <volume>8</volume>: <fpage>33</fpage>–<lpage>45</lpage>.</citation></ref>
<ref id="bibr3-0333102412470216"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milner</surname><given-names>PM</given-names></name></person-group>. <article-title>Note on a possible correspondence between the scotomas of migraine and spreading depression of Leão</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> <year>1958</year>; <volume>10</volume>: <fpage>705</fpage>–<lpage>705</lpage>.</citation></ref>
<ref id="bibr4-0333102412470216"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>M</given-names></name></person-group>. <article-title>On the possible relation of spreading cortical depression to classical migraine</article-title>. <source>Cephalalgia</source> <year>1985</year>; <volume>5</volume>(<supplement>Suppl 2</supplement>): <fpage>47</fpage>–<lpage>51</lpage>.</citation></ref>
<ref id="bibr5-0333102412470216"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayata</surname><given-names>C</given-names></name></person-group>. <article-title>Cortical spreading depression triggers migraine attack: Pro</article-title>. <source>Headache</source> <year>2010</year>; <volume>50</volume>: <fpage>725</fpage>–<lpage>730</lpage>.</citation></ref>
<ref id="bibr6-0333102412470216"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moskowitz</surname><given-names>MA</given-names></name><name><surname>Nozaki</surname><given-names>K</given-names></name><name><surname>Kraig</surname><given-names>RP</given-names></name></person-group>. <article-title>Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms</article-title>. <source>J Neurosci</source> <year>1993</year>; <volume>13</volume>: <fpage>1167</fpage>–<lpage>1177</lpage>.</citation></ref>
<ref id="bibr7-0333102412470216"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunkler</surname><given-names>PE</given-names></name><name><surname>Kraig</surname><given-names>RP</given-names></name></person-group>. <article-title>Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents</article-title>. <source>Hippocampus</source> <year>2003</year>; <volume>13</volume>: <fpage>835</fpage>–<lpage>844</lpage>.</citation></ref>
<ref id="bibr8-0333102412470216"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buzzi</surname><given-names>MG</given-names></name><name><surname>Bonamini</surname><given-names>M</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name></person-group>. <article-title>Neurogenic model of migraine</article-title>. <source>Cephalalgia</source> <year>1995</year>; <volume>15</volume>: <fpage>277</fpage>–<lpage>280</lpage>.</citation></ref>
<ref id="bibr9-0333102412470216"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolay</surname><given-names>H</given-names></name><name><surname>Reuter</surname><given-names>U</given-names></name><name><surname>Dunn</surname><given-names>AK</given-names></name><etal/></person-group>. <article-title>Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model</article-title>. <source>Nat Med</source> <year>2002</year>; <volume>8</volume>: <fpage>136</fpage>–<lpage>142</lpage>.</citation></ref>
<ref id="bibr10-0333102412470216"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kainz</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Activation of central trigeminovascular neurons by cortical spreading depression</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>855</fpage>–<lpage>865</lpage>. <comment><bold>**Direct demonstration using electrophysiological recordings from nucleus caudalis that cortical spreading depression is capable of activating downstream pain pathways</bold></comment>.</citation></ref>
<ref id="bibr11-0333102412470216"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Noseda</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Activation of meningeal nociceptors by cortical spreading depression: Implications for migraine with aura</article-title>. <source>J Neurosci</source> <year>2010</year>; <volume>30</volume>: <fpage>8807</fpage>–<lpage>8814</lpage>.</citation></ref>
<ref id="bibr12-0333102412470216"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Ayata</surname><given-names>C</given-names></name></person-group>. <article-title>Cortical spreading depression and migraine</article-title>. <source>Curr Neurol Neurosci Rep</source> <year>2010</year>; <volume>10</volume>: <fpage>167</fpage>–<lpage>173</lpage>.</citation></ref>
<ref id="bibr13-0333102412470216"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayata</surname><given-names>C</given-names></name></person-group>. <article-title>Spreading depression: From serendipity to targeted therapy in migraine prophylaxis</article-title>. <source>Cephalalgia</source> <year>2009</year>; <volume>29</volume>: <fpage>1095</fpage>–<lpage>1114</lpage>.</citation></ref>
<ref id="bibr14-0333102412470216"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayata</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Kudo</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Suppression of cortical spreading depression in migraine prophylaxis</article-title>. <source>Ann Neurol</source> <year>2006</year>; <volume>59</volume>: <fpage>652</fpage>–<lpage>661</lpage>. <comment><bold>**First comprehensive investigation of the impact of several migraine prophylactic drugs on spreading depression susceptibility as a common final mechanism of action</bold></comment>.</citation></ref>
<ref id="bibr15-0333102412470216"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogdanov</surname><given-names>VB</given-names></name><name><surname>Multon</surname><given-names>S</given-names></name><name><surname>Chauvel</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Migraine preventive drugs differentially affect cortical spreading depression in rat</article-title>. <source>Neurobiol Dis</source> <year>2011</year>; <volume>41</volume>: <fpage>430</fpage>–<lpage>435</lpage>.</citation></ref>
<ref id="bibr16-0333102412470216"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Dileköz</surname><given-names>E</given-names></name><name><surname>Kudo</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Oxcarbazepine does not suppress cortical spreading depression</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>537</fpage>–<lpage>542</lpage>.</citation></ref>
<ref id="bibr17-0333102412470216"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Dileköz</surname><given-names>E</given-names></name><name><surname>Kudo</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Gabapentin suppresses cortical spreading depression susceptibility</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2010</year>; <volume>30</volume>: <fpage>1588</fpage>–<lpage>1592</lpage>.</citation></ref>
<ref id="bibr18-0333102412470216"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unekawa</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>Y</given-names></name><name><surname>Toriumi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Suppressive effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats</article-title>. <source>Cephalalgia</source> <year>2012</year>; <volume>32</volume>: <fpage>518</fpage>–<lpage>527</lpage>.</citation></ref>
<ref id="bibr19-0333102412470216"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galeffi</surname><given-names>F</given-names></name><name><surname>Somjen</surname><given-names>GG</given-names></name><name><surname>Foster</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Simultaneous monitoring of tissue PO(2) and NADH fluorescence during synaptic stimulation and spreading depression reveals a transient dissociation between oxygen utilization and mitochondrial redox state in rat hippocampal slices</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2011</year>; <volume>31</volume>: <fpage>626</fpage>–<lpage>639</lpage>.</citation></ref>
<ref id="bibr20-0333102412470216"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DA</given-names></name><name><surname>Foster</surname><given-names>KA</given-names></name><name><surname>Galeffi</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Differences in O(2) availability resolve the apparent discrepancies in metabolic intrinsic optical signals in vivo and in vitro</article-title>. <source>Trends Neurosci</source> <year>2007</year>; <volume>30</volume>: <fpage>390</fpage>–<lpage>398</lpage>.</citation></ref>
<ref id="bibr21-0333102412470216"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>I</given-names></name><name><surname>Fifkova</surname><given-names>E</given-names></name><name><surname>Bures</surname><given-names>J</given-names></name></person-group>. <article-title>Limits of spreading depression in pigeon striatum</article-title>. <source>J Comp Neurol</source> <year>1963</year>; <volume>121</volume>: <fpage>485</fpage>–<lpage>492</lpage>.</citation></ref>
<ref id="bibr22-0333102412470216"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Harreveld</surname><given-names>A</given-names></name><name><surname>Stamm</surname><given-names>JS</given-names></name><name><surname>Christensen</surname><given-names>E</given-names></name></person-group>. <article-title>Spreading depression in rabbit, cat and monkey</article-title>. <source>Am J Physiol</source> <year>1956</year>; <volume>184</volume>: <fpage>312</fpage>–<lpage>320</lpage>.</citation></ref>
<ref id="bibr23-0333102412470216"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tower</surname><given-names>DB</given-names></name><name><surname>Young</surname><given-names>OM</given-names></name></person-group>. <article-title>The activities of butyrylcholinesterase and carbonic anhydrase, the rate of anaerobic glycolysis, and the question of a constant density of glial cells in cerebral cortices of various mammalian species from mouse to whale</article-title>. <source>J Neurochem</source> <year>1973</year>; <volume>20</volume>: <fpage>269</fpage>–<lpage>278</lpage>.</citation></ref>
<ref id="bibr24-0333102412470216"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardner-Medwin</surname><given-names>AR</given-names></name></person-group>. <article-title>Possible roles of vertebrate neuroglia in potassium dynamics, spreading depression and migraine</article-title>. <source>J Exp Biol</source> <year>1981</year>; <volume>95</volume>: <fpage>111</fpage>–<lpage>127</lpage>.</citation></ref>
<ref id="bibr25-0333102412470216"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>T</given-names></name><name><surname>Bures</surname><given-names>J</given-names></name></person-group>. <article-title>The minimum volume of depolarized neural tissue required for triggering cortical spreading depression in rat</article-title>. <source>Exp Brain Res</source> <year>1971</year>; <volume>12</volume>: <fpage>238</fpage>–<lpage>249</lpage>.</citation></ref>
<ref id="bibr26-0333102412470216"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>KH</given-names></name><name><surname>Marrannes</surname><given-names>R</given-names></name><name><surname>Wauquier</surname><given-names>A</given-names></name></person-group>. <article-title>Spreading depression and central nervous system pharmacology</article-title>. <source>J Pharmacol Methods</source> <year>1988</year>; <volume>19</volume>: <fpage>1</fpage>–<lpage>21</lpage>.</citation></ref>
<ref id="bibr27-0333102412470216"><label>27</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>C</given-names></name><name><surname>Kraig</surname><given-names>RP</given-names></name></person-group> <article-title>The behaviour of extracellular ions during spreading depression</article-title>. In: <person-group person-group-type="editor"><name><surname>Zeuthen</surname><given-names>T</given-names></name></person-group> (ed.) <source>The application of ion-selective microelectrodes</source>, <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>1981</year>, pp. <fpage>217</fpage>–<lpage>238</lpage>.</citation></ref>
<ref id="bibr28-0333102412470216"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Yuzawa</surname><given-names>I</given-names></name><name><surname>Dileköz</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>413</fpage>–<lpage>418</lpage>.</citation></ref>
<ref id="bibr29-0333102412470216"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>KH</given-names></name><name><surname>Marrannes</surname><given-names>R</given-names></name><name><surname>De Prins</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Strength-duration properties of cathodal pulses eliciting spreading depression in rat cerebral cortex</article-title>. <source>Brain Res</source> <year>1987</year>; <volume>404</volume>: <fpage>361</fpage>–<lpage>364</lpage>.</citation></ref>
<ref id="bibr30-0333102412470216"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Dileköz</surname><given-names>E</given-names></name><name><surname>Kudo</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1</article-title>. <source>J Clin Invest</source> <year>2009</year>; <volume>119</volume>: <fpage>99</fpage>–<lpage>109</lpage>.</citation></ref>
<ref id="bibr31-0333102412470216"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Obrenovitch</surname><given-names>TP</given-names></name><name><surname>Urenjak</surname><given-names>J</given-names></name></person-group>. <article-title>Effects of the nitric oxide donor, DEA/NO on cortical spreading depression</article-title>. <source>Neuropharmacology</source> <year>2003</year>; <volume>44</volume>: <fpage>949</fpage>–<lpage>957</lpage>.</citation></ref>
<ref id="bibr32-0333102412470216"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obrenovitch</surname><given-names>TP</given-names></name><name><surname>Urenjak</surname><given-names>J</given-names></name><name><surname>Zilkha</surname><given-names>E</given-names></name></person-group>. <article-title>Intracerebral microdialysis combined with recording of extracellular field potential: A novel method for investigation of depolarizing drugs in vivo</article-title>. <source>Br J Pharmacol</source> <year>1994</year>; <volume>113</volume>: <fpage>1295</fpage>–<lpage>1302</lpage>.</citation></ref>
<ref id="bibr33-0333102412470216"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>KC</given-names></name><name><surname>Romero Reyes</surname><given-names>M</given-names></name><name><surname>López Valdés</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>Reduced threshold for cortical spreading depression in female mice</article-title>. <source>Ann Neurol</source> <year>2007</year>; <volume>61</volume>: <fpage>603</fpage>–<lpage>606</lpage>.</citation></ref>
<ref id="bibr34-0333102412470216"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayata</surname><given-names>C</given-names></name><name><surname>Shimizu-Sasamata</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>EH</given-names></name><etal/></person-group>. <article-title>Impaired neurotransmitter release and elevated threshold for cortical spreading depression in mice with mutations in the alpha1A subunit of P/Q type calcium channels</article-title>. <source>Neuroscience</source> <year>2000</year>; <volume>95</volume>: <fpage>639</fpage>–<lpage>645</lpage>.</citation></ref>
<ref id="bibr35-0333102412470216"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>C</given-names></name><name><surname>Nozari</surname><given-names>A</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>The impact of anesthetics and hyperoxia on cortical spreading depression</article-title>. <source>Exp Neurol</source> <year>2008</year>; <volume>212</volume>: <fpage>201</fpage>–<lpage>206</lpage>.</citation></ref>
<ref id="bibr36-0333102412470216"><label>36</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Bures</surname><given-names>J</given-names></name><name><surname>Buresova</surname><given-names>O</given-names></name><name><surname>Krivanek</surname><given-names>J</given-names></name></person-group>. <source>The mechanism and applications of Leao's spreading depression of electroencephalographic activity</source>, <publisher-loc>New York</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>1974</year>.</citation></ref>
<ref id="bibr37-0333102412470216"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Topiramate inhibits cortical spreading depression in rat and cat: Impact in migraine aura</article-title>. <source>Neuroreport</source> <year>2005</year>; <volume>16</volume>: <fpage>1383</fpage>–<lpage>1387</lpage>.</citation></ref>
<ref id="bibr38-0333102412470216"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>PR</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na+ ion channel blockade</article-title>. <source>Brain Res</source> <year>2008</year>; <volume>1229</volume>: <fpage>27</fpage>–<lpage>36</lpage>.</citation></ref>
<ref id="bibr39-0333102412470216"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>PR</given-names></name><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>519</fpage>–<lpage>527</lpage>.</citation></ref>
<ref id="bibr40-0333102412470216"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nozari</surname><given-names>A</given-names></name><name><surname>Dileköz</surname><given-names>E</given-names></name><name><surname>Sukhotinsky</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Microemboli may link spreading depression migraine aura and patent foramen ovale</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>221</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr41-0333102412470216"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bockhorst</surname><given-names>KH</given-names></name><name><surname>Smith</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>A quantitative analysis of cortical spreading depression events in the feline brain characterized with diffusion-weighted MRI</article-title>. <source>J Magn Reson Imaging</source> <year>2000</year>; <volume>12</volume>: <fpage>722</fpage>–<lpage>733</lpage>.</citation></ref>
<ref id="bibr42-0333102412470216"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>KC</given-names></name><name><surname>Beltrán-Parrazal</surname><given-names>L</given-names></name><name><surname>López-Valdés</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>Distinct vascular conduction with cortical spreading depression</article-title>. <source>J Neurophysiol</source> <year>2007</year>; <volume>97</volume>: <fpage>4143</fpage>–<lpage>4151</lpage>.</citation></ref>
<ref id="bibr43-0333102412470216"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuzawa</surname><given-names>I</given-names></name><name><surname>Sakadžić</surname><given-names>S</given-names></name><name><surname>Srinivasan</surname><given-names>VJ</given-names></name><etal/></person-group>. <article-title>Cortical spreading depression impairs oxygen delivery and metabolism in mice</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2012</year>; <volume>32</volume>: <fpage>376</fpage>–<lpage>386</lpage>.</citation></ref>
<ref id="bibr44-0333102412470216"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sukhotinsky</surname><given-names>I</given-names></name><name><surname>Dileköz</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Chronic daily cortical spreading depressions suppress spreading depression susceptibility</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>1601</fpage>–<lpage>1608</lpage>.</citation></ref>
<ref id="bibr45-0333102412470216"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Baum</surname><given-names>MJ</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><etal/></person-group>. <article-title>Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>564</fpage>–<lpage>568</lpage>.</citation></ref>
<ref id="bibr46-0333102412470216"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chazot</surname><given-names>PL</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Effects of NMDA receptor antagonists with different subtype selectivities on retinal spreading depression</article-title>. <source>Br J Pharmacol</source> <year>2012</year>; <volume>165</volume>: <fpage>235</fpage>–<lpage>244</lpage>.</citation></ref>
<ref id="bibr47-0333102412470216"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiedemann</surname><given-names>M</given-names></name><name><surname>Lyhs</surname><given-names>B</given-names></name><name><surname>Bartels</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>The pharmacological control of neuronal excitability in the retinal spreading depression model of migraine</article-title>. <source>Curr Med Chem</source> <year>2012</year>; <volume>19</volume>: <fpage>298</fpage>–<lpage>302</lpage>.</citation></ref>
<ref id="bibr48-0333102412470216"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Yuzawa</surname><given-names>I</given-names></name><name><surname>Qin</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice</article-title>. <source>J Neurosci</source> <year>2011</year>; <volume>31</volume>: <fpage>5755</fpage>–<lpage>5763</lpage>.</citation></ref>
<ref id="bibr49-0333102412470216"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Maagdenberg</surname><given-names>AM</given-names></name><name><surname>Pizzorusso</surname><given-names>T</given-names></name><name><surname>Kaja</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>High cortical spreading depression susceptibility and migraine-associated symptoms in Ca(v)2.1 S218L mice</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>85</fpage>–<lpage>98</lpage>.</citation></ref>
<ref id="bibr50-0333102412470216"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Maagdenberg</surname><given-names>AM</given-names></name><name><surname>Pietrobon</surname><given-names>D</given-names></name><name><surname>Pizzorusso</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression</article-title>. <source>Neuron</source> <year>2004</year>; <volume>41</volume>: <fpage>701</fpage>–<lpage>710</lpage>.</citation></ref>
<ref id="bibr51-0333102412470216"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sonn</surname><given-names>J</given-names></name><name><surname>Mayevsky</surname><given-names>A</given-names></name></person-group>. <article-title>Effects of anesthesia on the responses to cortical spreading depression in the rat brain in vivo</article-title>. <source>Neurol Res</source> <year>2006</year>; <volume>28</volume>: <fpage>206</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr52-0333102412470216"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitahara</surname><given-names>Y</given-names></name><name><surname>Taga</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The effects of anesthetics on cortical spreading depression elicitation and c-fos expression in rats</article-title>. <source>J Neurosurg Anesthesiol</source> <year>2001</year>; <volume>13</volume>: <fpage>26</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr53-0333102412470216"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>R</given-names></name><name><surname>Graf</surname><given-names>R</given-names></name><name><surname>Hubel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Halothane, but not alpha-chloralose, blocks potassium-evoked cortical spreading depression in cats</article-title>. <source>Brain Res</source> <year>1995</year>; <volume>699</volume>: <fpage>109</fpage>–<lpage>115</lpage>.</citation></ref>
<ref id="bibr54-0333102412470216"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guedes</surname><given-names>RC</given-names></name><name><surname>Barreto</surname><given-names>JM</given-names></name></person-group>. <article-title>Effect of anesthesia on the propagation of cortical spreading depression in rats</article-title>. <source>Braz J Med Biol Res</source> <year>1992</year>; <volume>25</volume>: <fpage>393</fpage>–<lpage>397</lpage>.</citation></ref>
<ref id="bibr55-0333102412470216"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>R</given-names></name><name><surname>Graf</surname><given-names>R</given-names></name><name><surname>Hübel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Reduction of infarct volume by halothane: Effect on cerebral blood flow or perifocal spreading depression-like depolarizations</article-title>. <source>J Cereb Blood Flow Metab</source> <year>1997</year>; <volume>17</volume>: <fpage>857</fpage>–<lpage>864</lpage>.</citation></ref>
<ref id="bibr56-0333102412470216"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piper</surname><given-names>RD</given-names></name><name><surname>Lambert</surname><given-names>GA</given-names></name></person-group>. <article-title>Inhalational anesthetics inhibit spreading depression: Relevance to migraine</article-title>. <source>Cephalalgia</source> <year>1996</year>; <volume>16</volume>: <fpage>87</fpage>–<lpage>92</lpage>.</citation></ref>
<ref id="bibr57-0333102412470216"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verhaegen</surname><given-names>M</given-names></name><name><surname>Todd</surname><given-names>MM</given-names></name><name><surname>Warner</surname><given-names>DS</given-names></name></person-group>. <article-title>The influence of different concentrations of volatile anesthetics on the threshold for cortical spreading depression in rats</article-title>. <source>Brain Res</source> <year>1992</year>; <volume>581</volume>: <fpage>153</fpage>–<lpage>155</lpage>.</citation></ref>
<ref id="bibr58-0333102412470216"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhir</surname><given-names>A</given-names></name><name><surname>Lossin</surname><given-names>C</given-names></name><name><surname>Rogawski</surname><given-names>MA</given-names></name></person-group>. <article-title>Propofol hemisuccinate suppresses cortical spreading depression</article-title>. <source>Neurosci Lett</source> <year>2012</year>; <volume>514</volume>: <fpage>67</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr59-0333102412470216"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sukhotinsky</surname><given-names>I</given-names></name><name><surname>Yaseen</surname><given-names>MA</given-names></name><name><surname>Sakadžić</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Perfusion pressure-dependent recovery of cortical spreading depression is independent of tissue oxygenation over a wide physiologic range</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2010</year>; <volume>30</volume>: <fpage>1168</fpage>–<lpage>1177</lpage>.</citation></ref>
<ref id="bibr60-0333102412470216"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sukhotinsky</surname><given-names>I</given-names></name><name><surname>Dilekoz</surname><given-names>E</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Hypoxia and hypotension transform the blood flow response to cortical spreading depression from hyperemia into hypoperfusion in the rat</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2008</year>; <volume>28</volume>: <fpage>1369</fpage>–<lpage>1376</lpage>.</citation></ref>
<ref id="bibr61-0333102412470216"><label>61</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Marrannes</surname><given-names>R</given-names></name><name><surname>Wauquier</surname><given-names>A</given-names></name><name><surname>Reid</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Effects of drugs on cortical spreading depression</article-title>. In: <person-group person-group-type="editor"><name><surname>Amery</surname><given-names>WK</given-names></name><name><surname>Wauquier</surname><given-names>A</given-names></name></person-group> (eds). <source>The prelude to the migraine attack</source>, <publisher-loc>London</publisher-loc>: <publisher-name>Balliere Tindall</publisher-name>, <year>1986</year>, pp. <fpage>158</fpage>–<lpage>173</lpage>.</citation></ref>
<ref id="bibr62-0333102412470216"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>AJ</given-names></name><name><surname>Smith</surname><given-names>SE</given-names></name><name><surname>Whittington</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Factors influencing the frequency of fluorescence transients as markers of peri-infarct depolarizations in focal cerebral ischemia</article-title>. <source>Stroke</source> <year>2000</year>; <volume>31</volume>: <fpage>214</fpage>–<lpage>222</lpage>.</citation></ref>
<ref id="bibr63-0333102412470216"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nedergaard</surname><given-names>M</given-names></name><name><surname>Astrup</surname><given-names>J</given-names></name></person-group>. <article-title>Infarct rim: Effect of hyperglycemia on direct current potential and [14C]2-deoxyglucose phosphorylation</article-title>. <source>J Cereb Blood Flow Metab</source> <year>1986</year>; <volume>6</volume>: <fpage>607</fpage>–<lpage>615</lpage>.</citation></ref>
<ref id="bibr64-0333102412470216"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gido</surname><given-names>G</given-names></name><name><surname>Katsura</surname><given-names>K</given-names></name><name><surname>Kristian</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Influence of plasma glucose concentration on rat brain extracellular calcium transients during spreading depression</article-title>. <source>J Cereb Blood Flow Metab</source> <year>1993</year>; <volume>13</volume>: <fpage>179</fpage>–<lpage>182</lpage>.</citation></ref>
<ref id="bibr65-0333102412470216"><label>65</label><citation citation-type="journal"><comment>Hoffmann U, Sukhotinsky I, Eikermann-Haerter K and Ayata C. Glucose modulation of spreading depression susceptibility. <italic>J Cereb Blood Flow Metab</italic>. Epub ahead of print 12 September 2012. DOI: 10.1038/jcbfm.2012.132</comment>.</citation></ref>
<ref id="bibr66-0333102412470216"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><etal/></person-group>. <article-title>Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research</article-title>. <source>PLoS Biol</source> <year>2010</year>; <volume>8</volume>: <fpage>e1000412</fpage>–<lpage>e1000412</lpage>.</citation></ref>
<ref id="bibr67-0333102412470216"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eikermann-Haerter</surname><given-names>K</given-names></name><name><surname>Can</surname><given-names>A</given-names></name><name><surname>Ayata</surname><given-names>C</given-names></name></person-group>. <article-title>Pharmacological targeting of spreading depression in migraine</article-title>. <source>Expert Rev Neurother</source> <year>2012</year>; <volume>12</volume>: <fpage>297</fpage>–<lpage>306</lpage>.</citation></ref>
</ref-list>
</back>
</article>